EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network

☰ Menu

Vladka Čurin Šerbec

Name of the laboratory

Center for the Production of Diagnostic Reagents and for Research
Blood Trasfusion Centre of Slovenia
Šlajmerjeva 6, SI-1000 Ljubljana, Slovenia
+ 386 1 5438 100

Members of the laboratory

Members: Center for the Production of Diagnostic Reagents and for Research
Head
Vladka Čurin Šerbec vladka.curin@ztm.si
Research Personnel
Tanja Vranac tanja.vranac@ztm.si
Uroš Rajčević uros.rajcevic@ztm.si
Maja Černilec maja.cernilec@ztm.si
PhD Students
Valerija Hladnik valerija.hladnik@ztm.si
Laboratory Engineers
Boštjan Smrekar bostjan.smrekar@ztm.si
Melita Gracar melita.gracar@ztm.si
Technicians
Marjana Šprohar marjana.sprohar@ztm.si

Laboratory activity

Center for the Production of Diagnostic Reagents and for Research (CPDRR) was established a decade ago. One of its main activities was the production of diagnostic reagents for blood grouping under GMP, based on mouse monoclonal antibodies, which were developed, validated, registered (and later licensed) by CPDRR.

Besides production, CPDRR had strong collaborations with pharmaceutical industry in Slovenia and abroad (development of diagnostic tools, based on polyclonal antibodies for quality control, development of panels of monoclonal antibodies »à la carte«, know-how; nine projects and scientific elaborates for the industry so far).

All the time CPDRR has been involved in research activities in biomedical field in Slovenia and internationally with monoclonal antibodies as one of the main research lines (ten research projects and twelve PhDs were ran so far). We have our own animal facility (with permanent permission of appropriate veterinary authority), as well as recombinant antibody facilities.

We are also an important partner of the University of Ljubljana, teaching students about theoretical and practical aspects of monoclonal antibody production and their use in research, diagnostics and in therapy.

Research activities

During last decade, a number of monoclonal antibodies were developed, validated, produced, licensed and patented by CPDRR. Besides monoclonal antibodies against antigens of the blood group system AB0, they are directed against cytokines (TNF, p55, p75, MIF), potential new tumor markers (billitranslocase) and prions. In the last case, a panel of mouse monoclonal antibodies were developed in order to: 1) prepare a new generation of diagnostic kit, which was proposed to the EU Commission; 2) study the pathogenesis of the disease; 3) C-terminally truncated form of prion protein was first described with the help of one of our monoclonal antibodies.

Techniques available

Publications (2012-present)

Members